← Back to patent-cliff list
TQC-3927
Tier C — Watch / tradeTQC-3927
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AChR, ADRB2
Indications (approved)：Chronic obstructive pulmonary disease, Asthma
Regional status
US
-
EU
-
China
Phase II
2026-06-03
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TQC-3927?
Approved indications include: Chronic obstructive pulmonary disease, Asthma.
When does the TQC-3927 patent expire?
No public expiry year is available for TQC-3927 yet; this page updates once verified.
How do I get a quote for TQC-3927 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29